Work

Quest for new biomarkers in atherosclerosis.

Year: 2013

Type: article

Abstract: The Cho and Baldan labs focus their efforts on novel pathways that control atherogenesis. MIF (Macrophage migration inhibitory factor) recruits macrophages to atherosclerotic lesions and activates the production of matrix proteinases, which in turn destabilize atherosclerotic plaques. On the other hand, miR-33 coordinates the expression of several sterol transporters essential for high-density lipoprotein metabolism and bile secretion. Thus, both MIF and miR-33 are promising therapeutic targets to manage patients at risk of developing atherosclerosis.

Source: Europe PMC (PubMed Central)

Authors: Yoonsang Cho, Angel Baldán

Institution: Saint Louis University

Language: English

Topic: Macrophage Migration Inhibitory Factor

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Heart, Lung, and Blood Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases

Awards: Therapeutic Application of Small Molecule MIF Inhibitors in Rheumatoid Arthritis, Control Sterol and Lipoprotein Homeostasis by miRNA